Overview
Owens & Minor misses analysts' expectations for Q3 revenue
However, adjusted EBITDA beats consensus
Company shifts focus to home-based care, with sale of Products & Healthcare Services
Outlook
Company reaffirms 2025 revenue guidance of $2.76 bln to $2.82 bln
Owens & Minor maintains 2025 adjusted EPS guidance of $1.02 to $1.07
Company expects 2025 adjusted EBITDA between $376 mln and $382 mln
Result Drivers
STRATEGIC SHIFT - Owens & Minor's sale of Products & Healthcare Services segment aligns with focus on home-based care, per CEO Edward A. Pesicka
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $697.30 mln | $1.13 bln (5 Analysts) |
Q3 Net Income | -$150.27 mln | ||
Q3 Adjusted EBITDA | Beat | $92.20 mln | $91.59 mln (5 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Owens & Minor Inc is $6.50, about 19.7% above its October 29 closing price of $5.22
Press Release: ID:nBw1NGQ9fa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)